Streetbeat News

ACST

Acasti Pharma Inc.

https://www.acastipharma.com

Industry

Biotechnology

Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Open

3.43

Mkt cap

34M

Volume

28K

High

3.45

P/E Ratio

-2.36

52-wk high

3.60

Low

3.20

Div yield

N/A

52-wk low

1.98

Acasti Pharma has rebranded as Grace Therapeutics, Inc. and will begin trading under the new ticker symbol 'GRCE' on Nasdaq starting October 28, 2024. A virtual key opinion leader event is scheduled for November 20.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2024 | 12:05 pm

HC Wainwright & Co. has reiterated its Buy rating for Acasti Pharma (NASDAQ:ACST) and maintained a price target of $12, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 5:34 pm

Craig-Hallum analyst Chase Knickerbocker maintains a Buy rating on Acasti Pharma (NASDAQ:ACST) and raises the price target from $6 to $8.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 4:12 pm

Acasti Pharma's shares rose following the announcement of completing patient enrollment for its Phase 3 strive-on safety trial.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 1:33 pm

Acasti Pharma has completed patient enrollment for its Phase 3 STRIVE-ON safety trial, which is a significant milestone in the development of its product pipeline.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 11:34 am

Acasti Pharma reported its Q1 2025 earnings per share (EPS) of $(0.24), an improvement from $(0.54) year-over-year.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 12:09 pm

Acasti Pharma has reached 50% enrollment in its pivotal Phase 3 STRIVE-ON safety trial. This milestone is significant for the company's development of its lead drug candidate, GTX-104, aimed at treating subarachnoid hemorrhage. The trial's progress is a positive indicator for the company's future prospects.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 8:06 pm

Acasti Pharma reported a significant improvement in its FY24 revenue, with a loss of $1.35 million compared to a loss of $5.71 million year-over-year.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 12:09 pm

Acasti Pharma (NASDAQ:ACST) reported a narrower Q3 loss of $(0.21) per share, improving from a loss of $(0.52) per share YoY, marking a 59.62% increase in performance.

Portfolio Pulse from Happy Mohamed

February 12, 2024 | 1:12 pm

Craig-Hallum analyst Chase Knickerbocker initiates coverage on Acasti Pharma (NASDAQ:ACST) with a Buy rating and a price target of $6.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 2:10 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.